Table 6.
Baseline clinical and pathological characteristics by time to surgery after diagnosis, The SJTU cohort.
| Characteristics | Total N = 1986 (%) |
≤ 1week N = 1487 (%) |
1–2 weeks N = 362 (%) |
> 2 weeks N = 137 (%) |
P value |
|---|---|---|---|---|---|
| Age (y/o) | |||||
| < 40 | 267 (13.4) | 177 (11.9) | 57 (15.7) | 33 (24.1) | < 0.001 |
| 40–49 | 706 (35.5) | 547 (36.8) | 119 (32.9) | 40 (29.2) | |
| 50–70 | 914 (46.0) | 697 (46.9) | 157 (43.4) | 60 (43.8) | |
| > 70 | 99 (5.0) | 66 (4.4) | 29 (8.0) | 4 (2.9) | |
| Menstrual status | |||||
| Pre/Peri- | 1111 (55.9) | 828 (55.7) | 199 (55.0) | 84 (61.3) | 0.410 |
| Post- | 875 (44.1) | 659 (44.3) | 163 (45.0) | 53 (38.7) | |
| CCI | |||||
| 0 | 1444 (72.7) | 1093 (73.5) | 249 (68.8) | 102 (74.5) | 0.029 |
| 1–2 | 414 (20.8) | 311 (20.9) | 82 (22.7) | 21 (15.3) | |
| 3 + | 128 (6.4) | 83 (5.6) | 31 (8.6) | 14 (10.2) | |
| Breast surgery | |||||
| BCS | 586 (29.5) | 457 (30.7) | 97 (26.8) | 32 (23.4) | 0.089 |
| Mastectomy | 1400 (70.5) | 1030 (69.3) | 265 (73.2) | 105 (76.7) | |
| Axillary surgery | |||||
| SLNB | 956 (48.1) | 745 (50.1) | 160 (44.2) | 51 (37.2) | 0.022 |
| ALND | 1014 (51.1) | 731 (49.2) | 198 (54.7) | 85 (62.0) | |
| NA | 16 (0.8) | 11 (0.7) | 4 (1.1) | 1 (0.7) | |
| Histology type | |||||
| IDC | 1775 (89.4) | 1341 (90.2) | 317 (87.6) | 117 (85.4) | 0.103 |
| Non-IDC | 211 (10.6) | 146 (9.8) | 45 (12.4) | 20 (14.6) | |
| Tumor size | |||||
| ≤ 2.0 cm | 960 (48.3) | 729 (49.0) | 169 (46.7) | 62 (45.3) | 0.549 |
| > 2.0 cm | 1026 (51.7) | 758 (51.0) | 193 (53.3) | 75 (54.7) | |
| ALN status | |||||
| Negative | 1114 (56.1) | 841 (56.6) | 204 (56.4) | 69 (50.4) | 0.374 |
| Positive | 872 (43.9) | 646 (43.4) | 158 (43.6) | 68 (49.6) | |
| Tumor stage | |||||
| I | 679 (34.2) | 526 (35.4) | 117 (32.3) | 36 (26.3) | 0.110 |
| II | 966 (48.6) | 700 (47.1) | 189 (52.2) | 77 (56.2) | |
| III | 341 (17.2) | 261 (17.6) | 56 (15.5) | 24 (17.5) | |
| Histological grade | |||||
| I | 125 (6.3) | 95 (6.4) | 21 (5.8) | 9 (6.6) | 0.845 |
| II | 1276 (64.2) | 962 (64.7) | 231 (63.8) | 83 (60.6) | |
| III | 368 (18.5) | 276 (18.6) | 64 (17.7) | 28 (20.4) | |
| NA | 217 (10.9) | 154 (10.4) | 46 (12.7) | 17 (12.4) | |
| ER | |||||
| Negative | 464 (23.4) | 343 (23.1) | 83 (22.9) | 38 (27.7) | 0.455 |
| Positive | 1522 (76.6) | 1144 (76.9) | 279 (77.1) | 99 (72.3) | |
| PR | |||||
| Negative | 581 (29.3) | 426 (28.6) | 113 (31.2) | 42 (30.7) | 0.587 |
| Positive | 1405 (70.7) | 1061 (71.4) | 249 (68.8) | 95 (69.3) | |
| HER2 | |||||
| Negative | 1501 (75.6) | 1131 (76.1) | 271 (74.9) | 99 (72.3) | 0.576 |
| Positive | 485 (24.4) | 356 (23.9) | 91 (25.1) | 38 (27.7) | |
| Ki67 | |||||
| < 14% | 485 (24.4) | 364 (24.5) | 84 (23.2) | 37 (27.0) | 0.674 |
| ≥ 14% | 1501 (75.6) | 1123 (75.5) | 278 (76.8) | 100 (73.0) | |
| Molecular subtype | |||||
| HR + /HER2 − | 1245 (62.7) | 935 (62.9) | 229 (63.3) | 81 (59.1) | 0.789 |
| HER2 + | 485 (24.4) | 356 (23.9) | 91 (25.1) | 38 (27.7) | |
| TNBC | 256 (12.9) | 196 (13.2) | 42 (11.6) | 18 (13.1) | |